Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is released by activated platelets into the circulation, and is mediator of endothelial dysfunction. 5-HT metabolism is known in immune system via specific 5-HT receptor, also in effects on the peripheral nervous system. Kinetic of 5-HT, tryptophan, kynurenine, MAO activity and IDO activity in human septic shock was never investigated.
Inclusion Criteria:
* Age above or equal to 18 years
* Strong presumption clinical sepsis
* Need for mechanical ventilation
* Body temperature above 38°C or below 36°C
* Heart rate above 90 bpm
* Systolic blood pressure of \<90mm Hg despite adequate fluid replacement or a need for vasopressors less than 3 hours
* Presence of at least one of the following criteria:
* Ratio of arterial oxygen tension over inspired fraction of oxygen of less than 300 mm Hg
* Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at least 1 h)
* Arterial lactate concentration above 2 mmol/L
* Consent signed
Exclusion Criteria:
* Age below 18 years
* Pregnancy
* Underlying disease with a poor prognosis, a life expectancy of less than 24 hours
* Depression or melancholy
* Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction
* Neuroendocrine tumors
* Obstructive cardiomyopathy or acute myocardial ischaemia
* Pulmonary embolism
* Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or withdraw aggressive therapies
* Inclusion in another clinical trial
* Patient who receive before inclusion one of the following treatment known to modify serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine, clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan, ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin, interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline, methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan, olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline, sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine, zolmitriptan.
* No consent
Locations (1)
CH Versailles - André Mignot Hospital
Le Chesnay, France
Outcomes
Primary Outcomes
Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors